Evaluation of 11C-methionine PET as a surrogate endpoint after treatment of grade 2 gliomas.
The aim of the present study was to assess the usefulness of positron emission tomography (PET) as a surrogate endpoint by analysing the uptake variability of 11C-methionine (MET) in follow-up scans.A total of 96 PET MET scans were re-evaluated in 32 patients with histologically confirmed supratentorial grade 2 gliomas. In untreated patients, all follow-up PET scans showed an increased tumour volume after median 68 weeks, but only 46% of cases had an increased hot spot uptake. An improved outcome was observed in patients with stable hot spot uptake per se (P = 0.07) and in combinations with minor increase in tumour volume (P = 0.02). After conventional therapy, 52% of PET scans showed a reduced hot spot uptake the first year and 43% were reduced after more than a year. Successful MET decline after therapy did not correlate with outcome. PET MET may be a promising surrogate endpoint after treatment of grade 2 gliomas. Evaluation of both hot spot activity and uptake volume on PET may strengthen the association with clinical outcome.
Ribom
Dan
D
Department of Neuroscience, Neurology, University Hospital, Uppsala, Sweden. dan.ribom@lthalland.se
Schoenmaekers
Marjoleine
M
Engler
Henry
H
Smits
Anja
A
D000293:Adolescent; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000493:pharmacokinetics*; D002247:Carbon Isotopes / Q000493:pharmacokinetics*; D049109:Cell Proliferation / Q000187:drug effects; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D005910:Glioma / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000628:therapy; D006801:Humans; D008297:Male; D008715:Methionine / Q000493:pharmacokinetics*; D008875:Middle Aged; D017063:Outcome Assessment, Health Care / Q000379:methods; D049268:Positron-Emission Tomography / Q000379:methods*; D011849:Radioactive Tracers; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D012189:Retrospective Studies; D015173:Supratentorial Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000628:therapy
D014408:Biomarkers, Tumor; D002247:Carbon Isotopes; D011849:Radioactive Tracers; D019275:Radiopharmaceuticals; D008715:Methionine
Cancer. 2001 Sep 15;92 (6):1541-9
11745233
J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9
11895036
Acta Radiol. 1987 May-Jun;28(3):225-9
2958026
Curr Opin Investig Drugs. 2002 Mar;3(3):492-9
12054102
J Clin Oncol. 2002 May 1;20(9):2267-76
11980997
J Nucl Med. 2001 Mar;42(3):432-45
11337520
Eur J Nucl Med. 2000 May;27(5):542-9
10853810
J Cancer Res Clin Oncol. 2001 Jan;127(1):2-8
11206266
Neurology. 1998 May;50(5):1316-22
9595980
Int J Radiat Oncol Biol Phys. 1996 Oct 1;36(3):549-56
8948338
Neurosurg Rev. 1999 Dec;22(4):210-4
10682929
J Nucl Med. 2000 Jul;41(7):1250-5
10914918
Ann Neurol. 2003 Apr;53(4):524-8
12666121
J Neurosurg. 2001 Nov;95(5):746-50
11702862
Eur J Nucl Med Mol Imaging. 2002 May;29(5):632-40
11976801
J Neurol Neurosurg Psychiatry. 1999 May;66(5):644-7
10209179
Eur J Nucl Med Mol Imaging. 2003 Jun;30(6):868-73
12692687
Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):43-52
10924970
Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):316-24
11872276
J Nucl Med. 1998 May;39(5):778-85
9591574
Acta Neurochir Suppl. 1997;68:133-8
9233429
Stereotact Funct Neurosurg. 1997;69(1-4 Pt 2):129-35
9711745
Eur J Nucl Med. 1996 May;23 (5):583-6
8698067